Celldex Therapeutics Stock
Price
Target price
€33.80
€33.80
-1.730%
-0.6
-1.730%
€61.99
19.07.24 / Tradegate
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
We can see a decrease in the price for Celldex Therapeutics. Compared to yesterday it has lost -€0.600 (-1.730%).
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 61 € shows a very positive potential of 80.47% compared to the current price of 33.8 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | -1.730% | -7.650% | 1.198% | 1.807% | -6.630% | -7.902% | 536.535% |
| Vaxart Inc. | -2.300% | 0.405% | -8.154% | -16.667% | 20.151% | -91.168% | - |
| Larimar Therapeutics Inc. | 0.580% | -4.972% | 14.667% | 202.817% | 110.784% | 4.878% | -28.718% |
| aTyr Pharma Inc | -3.310% | 0.690% | 1.389% | -19.337% | 13.178% | -60.541% | -57.496% |
Comments
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $58.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat